Product Description
Mechanisms of Action:
Novel Mechanism: No
Modality: Antibody
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
06/27/2023 |
PubMed |
Treatment of liver fibrosis: Past, current, and future. |
|
03/01/2023 |
PubMed |
Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis. |
|
05/18/2022 |
PubMed |
Changes in the gut microbiome associated with liver stiffness improvement in nonalcoholic steatohepatitis. |